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Abstract
Objective: Small for gestational age (SGA) infants comprise up to 50% of all stillbirths and a minority are detected before
birth. We aimed to develop and validate early pregnancy predictive models for SGA infants.
Methods: 5628 participants from SCOPE, a prospective study of nulliparous pregnant women, were interviewed at 1561
weeks’ gestation. Fetal anthropometry, uterine and umbilical Doppler studies were performed at 2061 weeks’. The cohort
was divided into training (n = 3735) and validation datasets (n = 1871). All-SGA (birthweight ,10th customised centile),
Normotensive-SGA (SGA with normotensive mother) and Hypertensive-SGA (SGA with mother who developed
hypertension) were the primary outcomes. Multivariable analysis was performed using stepwise logistic regression firstly
using clinical variables and then with clinical and ultrasound variables. Receiver operator curves were constructed and areas
under the curve (AUC) calculated.
Results: 633 infants (11.3%) in the whole cohort were SGA; 465 (8.3%) Normotensive-SGA and 165 (3.0%) Hypertensive-SGA.
In the training dataset risk factors for All-SGA at 1561 weeks’ included: family history of coronary heart disease, maternal
birthweight,3000 g and 3000 g to 3499 g compared with$3500 g,.12 months to conceive, university student, cigarette
smoking, proteinuria, daily vigorous exercise and diastolic blood pressure $80. Recreational walking $4 times weekly,
rhesus negative blood group and increasing random glucose were protective. AUC for clinical risk factors was 0.63. Fetal
abdominal or head circumference z scores ,10th centile and increasing uterine artery Doppler resistance at 2061 weeks’
were associated with increased risk. Addition of these parameters increased the AUC to 0.69. Clinical predictors of
Normotensive and Hypertensive-SGA were sub-groups of All-SGA predictors and were quite different. The combined clinical
and ultrasound AUC for Normotensive and Hypertensive-SGA were 0.69 and 0.82 respectively.
Conclusion: Predictors for SGA of relevance to clinical practice were identified. The identity and predictive potential differed
in normotensive women and those who developed hypertension.
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Introduction
Approximately 50% of non-anomalous stillborn infants are
small for gestational age (SGA) and survivors are at increased risk
of neurodevelopmental delay, cerebral palsy [1] and later
cardiovascular complications and diabetes [2]. Traditionally,
SGA has been defined using population-based birthweight centiles
but utilization of customized centiles has enabled identification of
additional small babies at higher risk of morbidity and mortality
[3,4].
In routine antenatal care, less than a quarter of all SGA babies
are identified before birth [5]. SGA infants who are recognized
and well managed before birth have been reported to have a four-
fold reduction in perinatal death and severe fetal distress [6].
Utilization of customized antenatal growth charts in routine
antenatal care has been associated with improvements in antenatal
identification of SGA infants with detection rates of up to 50%
[5,7] but there remains a need for early pregnancy tools which
would further increase the level of detection. Development of a
reliable early pregnancy risk prediction algorithm enabling
identification, monitoring and timely delivery of SGA infants has
the potential to reduce both morbidity and mortality in these
vulnerable infants. SGA infants can be broadly classified into two
main categories with distinct maternal phenotypes: SGA with a
normotensive mother (Normotensive-SGA) and SGA where the
mother has gestational hypertension, preeclampsia or chronic
hypertension (Hypertensive-SGA). We have previously reported
that Normotensive- SGA comprises approximately three quarters
of all SGA infants born to nulliparous women and that risk factors
for Normotensive-SGA and Hypertensive-SGA differ, suggesting
that they could be considered as distinct conditions from the
perspective of prediction [8].
Our primary aim was to develop clinical risk prediction models
for All-SGA, Normotensive-SGA and Hypertensive-SGA infants
using clinical data obtained at 15 weeks’ gestation and to
determine whether addition of fetal measurements and uterine
and umbilical artery Doppler data from the 20 week ultrasound
scan improved prediction based on clinical risk alone.
Materials and Methods
The participants were healthy nulliparous women with singleton
pregnancies recruited to the SCOPE (Screening for Pregnancy
Endpoints) study between November 2004 and February 2011 in
Auckland, New Zealand, Adelaide, Australia, Manchester, Leeds
and London, United Kingdom and Cork, Ireland. SCOPE (www.
scopestudy.net) was a prospective, multi-centre cohort study with
the main aim of developing screening tests to predict preeclampsia,
SGA infants and spontaneous preterm birth. Ethical approval was
obtained from the relevant institutional ethic committees respon-
sible for human experimentation and all women provided written
informed consent. In New Zealand, approval for the SCOPE
Figure 1. Flow chart of study population.
doi:10.1371/journal.pone.0070917.g001
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study was given by Northern Region Ethics Committee on 23/04/
2003 reference number: AKX/02/00/364, in Australia by
Central Northern Adelaide Health Service Ethics of Human
Research Committee on 02/09/2005 reference number: REC
1714/5/Application number 2005082, in London, Leeds and
Manchester by the NHS South East Research Ethics Committee,
South East Coast Strategic Health Authority, Kent on 19/01/
2007 reference number: 06/MRE01/98 and in Ireland by the
University College Cork, Teaching Hospital Research Ethics
Committee on 06/02/2008 reference number: ECM5(10)05/02/
08. Detailed methods have previously been described [9,10]. The
study is registered with Australian New Zealand Clinical Trials
Registry ACTRN12607000551493 at https://www.anzctr.org.au.
Women were recruited to the study at 1561 weeks’ gestation.
Those considered at high risk of preeclampsia, SGA or sponta-
neous preterm birth because of underlying medical conditions
(including known pre-existing chronic hypertension on antihyper-
tensive medication or with a blood pressure greater than 160/
100 mmHg at 15 weeks’ gestation), three or more previous
miscarriages or terminations of pregnancy, or who had received
interventions that may modify pregnancy outcome (such as low
dose aspirin) were excluded.
Table 1. Study population characteristics at 1561 weeks’ and pregnancy outcome.
Training Cohort Validation Cohort
SGA Not-SGA P value SGA Not-SGA P value
N=422 N=3313 N=211 N=1660
Maternal Characteristics
Maternal age (y) 28.6 (5.8) 28.6 (5.4) 0.94 28.5 (5.7) 28.9 (5.5) 0.40
Ethnicity 0.30 0.83
White 373 (88%) 2994 (91%) 191 (91%) 1487 (90%)
Maori or Pacific Islander* 10 (2%) 61 (2%) 3 (1%) 39 (2%)
Asian or Indian 23 (6%) 179 (5%) 12 (6%) 88 (5%)
Other{ 16 (4%) 79 (2%) 5 (2%) 46 (3%)
Primigravid 312 (74%) 2568 (78%) 0.09 154 (73%) 1285 (77%) 0.15
Single 48 (11%) 304 (9%) 0.15 31 (15%) 154 (9%) 0.009
No paid employment 75 (18%) 465 (14%) 0.04 43 (20%) 243 (15%) 0.03
,12 years education 168 (40%) 1223 (37%) 0.25 90 (43%) 635 (38%) 0.22
Smoking status ,0.0001 ,0.0001
Non smoker 286 (68%) 2538 (77%) 142 (67%) 1283 (77%)
Ceased smoking before15 wks 55 (13%) 444 (13%) 29 (14%) 225 (14%)
Current smoker 81 (19%) 331 (10%) 40 (19%) 152 (9%)
BMI category 0.02 0.06
,20.0 36 (8%) 221 (7%) 14 (7%) 131 (8%)
20.0–24.9 189 (45%) 1702 (51%) 87 (41%) 816 (49%)
25.0–29.9 117 (28%) 908 (27%) 69 (33%) 478 (29%)
$30 80 (19%) 482 (15%) 41 (19%) 235 (14%)
Maternal birthweight (g) 3163 (540) 3329 (559) 0.0001 3184(499) 3319 (523) ,0.001
N= 395 N= 3144 N= 197 N= 1583
Systolic BP (mmHg) 108 (11) 107 (10) 0.004 109 (11) 107 (11) 0.01
Diastolic BP (mmHg) 66 (9) 65 (8) 0.01 67 (8) 65 (8) 0.002
Pregnancy Outcome
Hypertensive Pregnancy` 109 (26%) 409 (12%) ,0.0001 59 (28%) 183 (11%) ,0.0001
Birthweight (g) 2641 (557) 3500 (516) ,0.0001 2627 (614) 3512 (483) ,0.0001
Gestational age at delivery (wks) 39.0 (3.4) 39.7 (2.0) ,0.0001 38.5 (3.6) 39.8 (1.8) ,0.0001
Customised birthweight centile 4.7 (3) 53.0 (26) ,0.0001 4.7 (3) 53.3 (26) ,0.0001
Total preterm births (,37 wks) 54 (13%) 177 (5%) ,0.0001 40 (19%) 80 (5%) ,0.0001
Admitted to neonatal unit* 82 (19%) 340 (10%) ,0.0001 61 (29%) 164 (10%) ,0.0001
Perinatal deaths 7 (1.7%) 15 (0.5%) ,0.0001 5 (2%) 1 (0.1%) ,0.0001
Results expressed as N (%) or mean (SD) as appropriate;
*includes 44 Maori and 27 Pacific Islanders in the training and 27 Maori and 15 Pacific Islanders in the validation set;
{includes 15 Australian Aborigines in the training and 8 in the validation set.
`Hypertensive pregnancy defined as preeclampsia, gestational hypertension or mild chronic hypertension.
doi:10.1371/journal.pone.0070917.t001
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Women who agreed to participate were interviewed and
examined by a research midwife at 1561 and 2061 weeks of
gestation and underwent ultrasound examination at 2061 weeks.
Detailed clinical data were collected at each time point, including
demographic information, medical history, the woman’s birth-
weight, previous early pregnancy losses (miscarriage or termina-
tion of pregnancy), history of infertility, duration of sexual
relationship, gynaecological history and family history of obstetric
complications and medical disorders. A family history of metabolic
disease was defined as the participant’s mother or father having
one or more of the following conditions: type 2 diabetes, chronic
hypertension, history of cerebrovascular accident or ischaemic
heart disease. Current pregnancy data included vaginal bleeding,
hyperemesis, dietary information, folic acid and low dose
multivitamin supplementation, smoking, alcohol and recreational
drug use. A vegetarian diet was defined as no consumption of meat
or fish. Binge drinking was defined as drinking 6 or more units of
alcohol at one time point. Vigorous exercise was defined as
exercise leading to heavy breathing or being out of breath [11] and
recreational walking as the number of times per week the woman
engaged in walking for recreation or exercise during the previous
month. Maternal random glucose (mmol/L) and proteinuria were
also measured at 1561 weeks’ gestation. Proteinuria at 15 weeks’
gestation was defined as a dipstick $1+ or spot urine protein:
creatinine ratio measurement $30 mg/mmol. At the time of
interview, data were entered into a secure internet-accessed,
auditable database (MedSciNet AB, Sweden).
Ultrasound examination performed at 2061 weeks’ gestation
included fetal anthropometric measurements (biparietal diameter,
femur length and head and abdominal circumference) and
Doppler waveform analysis of the umbilical and uterine arteries
[12]. Mean uterine resistance index (RI) was calculated from the
left and right uterine RI. If only a left or right RI was available,
this was used as ‘mean RI’ (n = 95). Women who did not have
growth measurements or uterine or umbilical artery Doppler
assessment performed at 20 weeks were excluded from the analysis
of ultrasound factors.
Participants were followed prospectively, with pregnancy
outcome data and infant measurements recorded by research
midwives, usually within 72 hours of birth.
Table 2. Maternal characteristics and pregnancy outcome amongst Normotensive and Hypertensive-SGA pregnancies.
Normotensive-SGA Hypertensive-SGA P value
N=313 (11.4%) N=109 (2.9%) P value
Maternal Characteristics
Maternal age (years) 28.4 (5.8) 29.3 (5.8) 0.18
Ethnicity 0.50
White 273 (87%) 100 (92%)
Maori or Pacific Islander* 8 (2%) 2 (2%)
Indian 9 (3%) 4 (3%)
Asian 9 (3%) 1 (1%)
Other{ 14 (5%) 2 (2%)
Primigravid 231 (74%) 81 (74%) 1.0
Socioeconomic index 41 (17) 38 (16) 0.19
Smoker at 1561 weeks 65 (21%) 16 (15%) 0.20
BMI category (kg/m2) ,0.0001
,20.0 6 (2%) 0 (0%)
20.0–24.9 179 (57%) 40 (37%)
25.0–29.9 81 (26%) 36 (33%)
.30 47 (15%) 33 (30%)
Participant’s birthweight (grams) 3166 (551) 3178 (463) 0.79
N= 292 N= 101
Systolic BP 1561 weeks 107 (11) 113 (12) ,0.0001
Diastolic BP 1561 weeks 64 (8) 70 (9) ,0.0001
Pregnancy Outcome
Birthweight (grams) 2686 (531) 2506 (611) 0.004
Gestational age at delivery (weeks) 39.3 (3.5) 38.3 (3.3) 0.01
Customised birthweight centile 5.0 (2.9) 3.8 (2.8) ,0.0001
Total preterm births (,37 weeks) 27 (9%) 27 (25%) ,0.0001
Admitted to neonatal unit 44 (14%) 38 (35%) ,0.0001
Perinatal deaths 5 (2%) 2 (2%)
Results expressed as N (%), mean (SD);
*includes 4 Maori and 6 Pacific Islanders;
{includes 5 Australian Aborigines.
doi:10.1371/journal.pone.0070917.t002
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Outcome Measures
All SGA was defined as birthweight ,10th customised centile,
where birthweight is adjusted for maternal height, booking weight,
ethnicity as well as delivery gestation and infant sex [13]. The
primary outcomes were: Normotensive-SGA defined as birth of an
SGA infant where the mother did not develop hypertension, and
Hypertensive-SGA defined as birth of an SGA infant where the
mother had gestational hypertension, preeclampsia and/or mild
chronic hypertension [9].
Definitions
Gestational hypertension: systolic BP$140 mmHg and/or diastolic
BP $90 mmHg on at least 2 occasions 4 h apart after 20 weeks’
gestation, but before the onset of labour. Preeclampsia: gestational
hypertension or postpartum hypertension (as defined above, but
developing for the first time after delivery) in association with
proteinuria (24 hour urinary protein $ 300 mg, or spot urine
protein: creatinine ratio $ 30 mg/mmol, or urine dipstick protein
$ 2+) or any multi-system complication of preeclampsia
[14,15,16]. Mild chronic hypertension: a systolic BP of 140–
159 mmHg and/or diastolic BP 90–99 mmHg, on more than
one reading, first identified at the 1561 or 2061 weeks’ gestation
SCOPE visit. None of these women had recognised or treated
hypertension before the pregnancy. Non-SGA referred to all women
in the remainder of the cohort who did not have SGA babies. This
group included pregnancies with other complications such as
spontaneous preterm birth or preeclampsia with a normally grown
baby. Perinatal deaths included stillbirths and terminations of pregnancy
after 20 weeks’ gestation [defined as birth of an infant at $20
weeks’gestation with no signs of life (n = 33)] and neonatal deaths
[defined as death of a live born infant in the first 28 days of life
(n = 7)]. Antenatal recognition of SGA was defined as SGA being
diagnosed on ultrasound before the date of delivery.
Table 3. Univariable and multivariable comparisons of clinical and ultrasound risk factors for All SGA by customised birthweight
centiles.
Training Cohort
N=3735 N=3541
Risk Factors SGA Non SGA
Univariable Odds
Ratio (95% CI){
Multivariable Odds
Ratio (95% CI)
Multivariable Odds
Ratio (95% CI){{
N=422 N=3313
15 week data AUC=0.66 AUC=0.73
Family history of coronary heart disease (father) 72 (17.1) 402 (12.1) 1.49 (1.13 to 1.96) 1.46 (1.10 to 1.93) 1.63 (1.22, 2.19)
Maternal birthweight (grams)* 3163 (539) 3329 (559)
,3000 138 (35%) 749 (24%) 2.18 (1.66 to 2.86) 2.09 (1.60 to 2.74) 1.98 (1.49, 2.63)
3000–3499 157 (40%) 1212 (38%) 1.53 (1.17 to 1.99) 1.56 (1.21 to 2.02) 1.56 (1.19, 2.05)
$3500 100 (25%) 1183 (38%) 1.00 1.00 1.00
.12 months to conceive 89 (21%) 526 (16%) 1.42 (1.10 to 1.82) 1.48 (1.14 to 1.91) 1.36 (1.03, 1.78)
Currently attending university 20 (5%) 88 (3%) 1.82 (1.12 to 3.00) 1.91 (1.14 to 3.19) 1.87 (1.08, 3.24)
Currently smoking 81 (19%) 331 (10%) 2.14 (1.64 to 2.80) 2.15 (1.63 to 2.83) 2.13 (1.59, 2.84)
Proteinuria 28 (7%) 126(4%) 1.80 (1.18 to 2.74) 1.61 (1.04 to 2.50) 1.57 (0.99, 2/49)
Vigorous exercise $1 x/day 12 (3%) 29 (0.9%) 3.33 (1.69 to 6.57) 3.78 (1.87 to 7.66) 3.22 (1.43, 7.29)
Diastolic BP$80 mmHg 39 (9%) 176 (5%) 1.82 (1.26 to 2.61) 1.84 (1.27 to 2.68) 1.82 (1.21, 2.73)
Recreational walking $4 x/week 69 (17%) 701 (21%) 0.73 (0561 to 0.96) 0.72 (0.55 to 0.96) 0.73 (0.55, 0.98)
Rhesus negative blood group 41(10%) 512 (15%) 0.59 (0.42 to 0.82) 0.58 (0.41 to 0.81) 0.60 (0.42, 0.85)
Random glucose per unit increase 5.2 (0.9) 5.3 (1.0) 0.87 (0.78 to 0.98) 0.85 (0.76 to 0.95) 0.84 (0.75, 0.95)
20 week scan data{{ N=401 N=3174
Head circumference z score ,10th centile** 66 (17%) 267 (8%) 2.14 (1.60 to 2.87) 1.79 (1.30 to 2.46)
Abdominal circumference z score ,10th centile*** 64 (16%) 278 (9%) 1.98 (1.47 to 2.65) 1.73 (1.25 to 2.39)
Average uterine resistance index 0.61 (0.10) 0.56 (0.10)
,0.5 57 (14%) 844 (26%) 1.0 1.0
0.5 to 0.59 111 (28%) 1259 (40%) 1.31 (0.94 to 1.82) 1.31 (0.93 to 1.84)
0.6 to 0.69 151 (38%) 752 (24%) 2.97 (2.16 to 4.10 ) 2.80 (2.01 to 3.90)
0.7 to 0.79 65 (16%) 259 (8%) 3.72 (2.54 to 5.44) 3.63 (2.44 to 5.39)
0.8 to 1.0 17 (4%) 60 (2%) 4.20 (2.30 to 7.66) 4.56 (2.45 to 8.48)
Data are mean (SD) number (%) as appropriate, italics indicate variable is protective.
*missing data numbers for woman’s birthweight (SGA n=27, no SGA 169 missing.
**missing data numbers for head circumference z score ,10th centile (SGA n= 2, no SGA n= 23 missing).
***missing data numbers for abdominal circumference z score ,10th centile (SGA n= 1, no SGA n= 12 missing).
{Unimputed data was used for univariable analyses.
{{Unimputed ultrasound data was added to the multivariable models derived from 15 week imputed data.
doi:10.1371/journal.pone.0070917.t003
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Datasets
The final SCOPE cohort for the SGA study population
comprised 5606 participants (Figure 1). To allow for model
generalization, the data were partitioned into a training set for
model fitting and a validation set for empirical validation.
Training and validation datasets were generated in a 2:1 ratio
by randomly splitting the total dataset, stratified by the geograph-
ical areas of Australasia and Europe. The datasets were checked
for major discrepancies in SCOPE centre or rates of SGA between
the training and validation sets.
Of the 1055 original and derived variables available to the
All-SGA, Normotensive-SGA and Hypertensive-SGA models,
113 were excluded as they were not applicable to prediction. A
further 46 variables were excluded as they were not general-
izable and 102 variables were excluded as they had .10%
missing data due to the variable being added to the database
after the initiation of the study, clinical laboratory data or work
related variables. Of the remaining 794 variables, univariable
analysis for association with All-SGA, Normotensive-SGA and
Hypertensive-SGA was performed and 579 All-SGA, 565
Normotensive-SGA and 544 Hypertensive-SGA variables were
then excluded as non-significant (P.0.1). Of the remaining
available variables [All-SGA (n= 215), Normotensive-SGA
(n= 229) and Hypertensive-SGA (n= 250)], the variables in
the final models were selected based on known potential risk
factors for SGA, ease of collection in the clinical setting and
potential applicability to future populations. The deleted
variables included those with a low cell count (,5) in the x2
test, lack of a priori knowledge regarding SGA prediction or
addressed by other variables which were retained in the models.
This resulted in 38 All-SGA variables (32 clinical and six 2061
week ultrasound variables), 26 Normotensive-SGA variables (20
clinical and six 2061 week ultrasound variables) and 17
Hypertensive-SGA variables (13 clinical and four 2061 week
ultrasound variables) being available to train the three
multivariable models (variables listed in Table S1).
The relationship between SGA and the continuous variables
available for inclusion in the models was explored using
Generalised Additive Models (GAMs) in SAS 9.1 (SAS Institute
Inc, Cary, NC) to determine the nature of the relationship and
whether variables should be available to the model(s) continuously
or categorically. For maternal birthweight, systolic and diastolic
blood pressure, and mean uterine artery Doppler resistance index,
the relationship with SGA was not linear and these variables were
categorised to best reflect the associations in each model.
Among the 15 week clinical variables available to any of the
three models, data were complete for 26 and seven variables had
data missing for,1.5% of participants. For the remaining variable
(maternal birthweight) 5.1% had missing data. Missing continuous
data variables were imputed using Expectation Maximization
(n= 3) or median (n = 2) and for categorical data variables the
mode was used (n= 3).
Statistical Analysis
Univariable analysis was performed using clinical variables
obtained at the 1561 weeks’ gestation SCOPE interview, and the
fetal measurements and Doppler parameters obtained at the 2061
weeks’ gestation ultrasound scan using the unimputed database.
The comparison group for All-SGA was Not-SGA, for ‘Normo-
tensive-SGA’ was ‘Not Normotensive-SGA’ (which comprised all
women in the remainder of the cohort who did not have
‘Normotensive-SGA’ including those with ‘Hypertensive-SGA’),
and for ‘Hypertensive-SGA’ the comparison group was ‘Not
Hypertensive-SGA’ (which comprised all women in the remainder
Figure 2. Receiver operating characteristics curves based on
training and validation models of clinical risk factors at 15
weeks’ and ultrasound factors at 20 weeks’ gestation. A. All SGA
B. Normotensive SGA C. Hypertensive SGA.
doi:10.1371/journal.pone.0070917.g002
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of the cohort who did not have ‘Hypertensive –SGA’ including
those with ‘Normotensive-SGA’). Other pregnancy pathologies
were therefore included in the comparison groups.
Student’s t-test or Wilcoxon rank sum tests were used for
comparison of continuous variables. Categorical variables were
compared using chi-square or Fisher’s exact test. Multivariable
analysis was performed using both forward and backward stepwise
logistic regression firstly using clinical variables only, and then with
clinical and ultrasound variables, to compare All-SGA, Normo-
tensive-SGA and Hypertensive-SGA with their respective com-
parison groups. All final models were the same when the forward
and backward methods were used. For the multivariable analyses
using the 15 week clinical variables, imputed databases were used
but for the ultrasound analyses women with missing data were not
included in the analysis. A significance level of less than or equal to
0.05 was used in multivariable analyses. Receiver operator curves
were produced for all multivariable models along with the
associated area under the curve (AUC) and screening test
characteristics reported at a 25%, 10% and 5% false positive rate
[17]. SAS 9.1(SAS Institute Inc, Cary, NC) was used for all
statistical analyses.
Results
Five thousand six hundred and ninety healthy nulliparous
women with singleton pregnancies were recruited to the SCOPE
(Screening for Pregnancy Endpoints) study between November
2004 and February 2011 in Auckland, New Zealand, Adelaide,
Australia, London, Leeds and Manchester, United Kingdom and
Cork, Ireland and follow up was complete in 98.9% of participants
(Figure 1) (STROBE Statement: Table S2).
To allow for model generalization, the data were divided into a
training set for model fitting (n = 3735) and a validation set
(n = 1871) (Table 1). Of the 422 (11%) infants in the training
database who were SGA by customized centiles, 313 (8%) were
born to normotensive mothers (Normotensive-SGA), 109 (3%) to
hypertensive mothers (Hypertensive-SGA) (Table 2). In the
validation database, 211 (11%) infants were SGA of whom 152
(8%) were Normotensive-SGA and 59 (3%) Hypertensive-SGA.
Comparing training and validation sets, amongst the Hyperten-
sive-SGA pregnancies, 44 (40%) and 26 (44%) women respectively
had preeclampsia; 63 (58%), and 33 (56%) had gestational
hypertension; 2 (2%) and none had mild chronic hypertension
alone. Antenatal recognition of SGA was not significantly different
Table 4. Univariable and multivariable comparisons of clinical and ultrasound risk factors for Normotensive-SGA by customised
birthweight centiles.
Training Cohort
N=3735 N=3541
Risk Factors NT SGA Non NT SGA
Univariable Odds
Ratio (95% CI) {
Multivariable Odds
Ratio (95% CI)
Multivariable Odds
Ratio (95% CI) {{
N=313 N=3422
15 week data AUC=0.66 AUC=0.71
Maternal birthweight (grams)* 3166 (551) 3323 (558)
,3000 105 (36%) 782 (24%) 2.05 (1.51 to 2.78) 2.01 (1.49 to 2.72) 1.88 (1.37 to 2.58)
3000–3499 110 (37%) 1259 (39%) 1.33 (0.99 to 1.80) 1.38 (1.03 to 1.85) 1.37 (1.01 to 1.85)
$3500 79 (27%) 1204 (37%) 1.0 1.00 1.00
Currently attending university 19 (6%) 89 (3%) 2.42 (1.46 to 4.03) 2.52 (1.49 to 4.25) 2.50 (1.43 to 4.37)
Currently smoking 65 (21%) 347 (10%) 2.32 (1.73 to 3.12) 2.29 (1.69 to 3.09) 2.22 (1.62 to 3.04)
Vigorous exercise $1 x/day 10 (3%) 31 (0.9%) 3.63 (1.76 to 7.48) 3.97 (1.87 to 8.41) 3.91 (1.6 to 9.07)
Recreational walking $4 x/week 45 (15%) 725 (21%) 0.63 (0.45 to 0.87) 0.61 (0.44 to 0.85) 0.58 (0.41 to 0.83)
Rhesus negative blood group 25 (8%) 528 (15%) 0.48 (0.31 to 0.72) 0.48 (0.31 to 0.73) 0.51 (0.33 to 0.78)
Random glucose per unit increase 5.2 (0.9) 5.3 (1.0) 0.86 (0.76 to 0.97) 0.85 (0.75 to 0.96) 0.84 (0.73 to 0.96)
20 week scan data{{ N=298 N=3277
Head circumference z score ,10th centile** 50 (17%) 283 (9%) 2.13 (1.53 to 2.95) 1.70 (1.19 to 2.43)
Abdominal circumference z score ,10th centile*** 50 (17%) 292 (9%) 2.06 (1.49 to 2.86) 1.78 (1.25 to 2.54)
Average uterine resistance index 0.61 (0.10) 0.57 (0.10)
,0.5 40 (13%) 861 (26%) 1.0 1.0
0.5 to 0.59 94 (32%) 1276 (39%) 1.59 (1.08 to 2.32) 1.56 (1.06 to 2.30)
0.6 to 0.69 110 (37%) 793 (24%) 2.99 (2.05 to 4.34 ) 2.73 (1.86 to 4.00)
0.7 to 1.0 54 (18%) 347 (11%) 3.35 (2.19 to 5.14) 3.21 (2.07 to 4.97)
Data are mean (SD) number (%) as appropriate, italics indicate variable is protective.
*missing data numbers for woman’s birthweight (SGA n=19, no SGA 178 missing.
**missing data numbers for head circumference z score ,10th centile (SGA n= 2, no SGA n= 23 missing).
***missing data numbers for abdominal circumference z score ,10th centile (SGA n= 1, no SGA n= 12 missing).
{Unimputed data was used for univariate analyses.
{{Unimputed ultrasound data was added to the multivariable models derived from 15 week imputed data.
NT SGA=birth of an SGA infant where the mother did not develop hypertension.
Non NT SGA= all women in the remainder of the cohort who did not have Normotensive-SGA pregnancies.
doi:10.1371/journal.pone.0070917.t004
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between normotensive mothers with SGA infants (109, 23%) and
hypertensive mothers with SGA infants (46, 28%), p = 0.35.
Clinical variables associated with prediction of All-SGA in the
training dataset model (Table 3) included: family history of
coronary heart disease, maternal birthweight ,3000 g, and
between 3000 g and 3499 g compared with $3500 g, taking
.12 months to conceive, attending university, cigarette smoking,
the presence of proteinuria, daily vigorous exercise and diastolic
BP$80. Recreational walking $4 times weekly, rhesus negative
blood group, and increasing random glucose were protective. The
AUC for clinical risk factors in the training dataset was 0.66. Fetal
abdominal or head circumference Z score ,10th centile and
increasing mean uterine artery Doppler resistance indices at 20
weeks were also associated with increased risk, and addition of
these ultrasound parameters to clinical risk factors resulted in an
AUC of 0.73. In the validation dataset, the AUC for clinical risk
factors alone was 0.63 and after addition of the ultrasound
parameters was 0.69 (Figure 2A).
Clinical variables associated with prediction of Normotensive-
SGA in the training dataset model (Table 4) were a sub-group of
those included in the All-SGA model. The AUC for clinical risk
factors in the training dataset was 0.66. Fetal abdominal or head
circumference Z score ,10th centile and increasing mean uterine
artery Doppler resistance indices at 2061 weeks’ were again
associated with increased risk, and addition of these ultrasound
parameters to clinical risk factors resulted in an AUC of 0.71. In
the validation dataset, the AUC for clinical risk factors alone was
0.62 and with the addition of the ultrasound parameters was 0.69
(Figure 2B).
Variables identified as predictors of Hypertensive-SGA in the
training database were predominantly a sub-group of All-SGA
predictors: taking greater than 12 months to conceive, a family
history of metabolic syndrome or coronary heart disease, low fruit
consumption, binge drinking, overweight and obesity, systolic
BP$120 mm Hg and diastolic BP$80 mm Hg (Table 5). As with
Normotensive-SGA, maternal birthweight ,3000 g and between
Table 5. Univariable and multivariable comparisons of clinical and ultrasound risk factors for Hypertensive-SGA by customised
birthweight centiles.
Training Cohort
N=3735 N=3541
Risk Factors HTSGA Non HTSGA
Univariable Odds
Ratio (95% CI) {
Multivariable Odds
Ratio (95% CI)
Multivariable Odds
Ratio (95% CI) {{
N=109 N=3626
At 15 weeks AUC=0.76 AUC=0.82
.12 months to conceive 28 (26%) 587 (16%) 1.79 (1.15 to 2.78) 1.70 (1.08 to 2.67) 1.64 (1.02 to 2.64)
Family history of metabolic syndrome (mother) 44 (40%) 936 (26%) 1.95 (1.32 to 2.87) 1.67 (1.11 to 2.51) 1.59 (1.04 to 2.44)
Family history of coronary heart disease (father) 25 (23%) 449 (12%) 2.11 (1.33 to 3.33) 1.77 (1.09 to 2.85) 1.85 (1.12 to 3.05)
Low fruit consumption in the past month` 58 (53%) 1413 (39%) 1.78 (1.22 to 2.61) 1.94 (1.30 to 2.89) 1.98 (1.30 to 3.00)
Any binge drinking during pregnancy 40 (37%) 841 (23%) 1.92 (1.29 to 2.86) 2.14 (1.42 to 3.23) 1.97 (1.28 to 3.04)
Maternal birthweight (grams) * 3179 (463) 3314 (561)
,3000 33 (33%) 854 (25%) 2.32 (1.33 to 4.04) 2.10 (1.22 to 3.62) 2.20 (1.24 to 3.90)
3000 to 3499 47 (47%) 1322 (39%) 2.14 (1.27 to 3.59) 2.09 (1.26 to 3.44) 2.22 (1.31 to 3.77)
$3500 21 (21%) 1262 (36%) 1.0 1.0 1.0
Body Mass Index (kg/m2)
,25 40 (37%) 2108 (58%) 1.0 1.0 1.00
25 to 29.9 36 (33%) 989 (27%) 1.92 (1.22 to 3.03) 1.47 (0.92 to 2.36) 1.46 (0.89 to 2.39)
$30.0 33 (30%) 529 (15%) 3.29 (2.05 to 5.26) 1.96 (1.18 to 3.27) 2.00 (1.18 to 3.38)
Systolic blood pressure $120 mmHg 38 (35%) 478 (13%) 3.53 (2.35 to 5.29) 1.97 (1.21 to 3.20) 2.03 (1.21 to 3.40)
Diastolic blood pressure $80 mmHg 25 (23%) 190 (5%) 5.38 (3.37 to 8.61) 2.87 (1.65 to 5.02) 2.66 (1.45 to 4.86)
20 week ultrasound scan data{{ N=103 N=3472
Average uterine Doppler resistance index 0.64 (0.12) 0.57 (0.10)
,0.5 17 (16%) 884 (25%) 1.00 1.00
0.5 to 0.59 17 (16%) 1353 (39%) 0.65 (0.33, 1.29) 0.63 (0.31, 1.25)
0.6 to 0.69 41 (40%) 862 (25%) 2.47 (1.39, 4.39) 2.29 (1.27, 4.13)
0.7 to 0.79 18 (18%) 306 (9%) 3.06 (1.56, 6.01) 2.72 (1.35, 5.47)
0.8 to 1.0 10 (10%) 67 (2%) 7.76 (3.42, 17.62) 7.83 (3.32, 18.45)
Data are mean (SD) number (%) as appropriate,
*missing data numbers for woman’s birthweight (SGA n=8, no SGA n= 188 missing).
{Unimputed data was used for univariate analyses.
{{Unimputed ultrasound data were added to the multivariable models derived from imputed 15 week data.
`,1serving of fruit/day.
HT SGA=birth of an SGA infant where the mother had gestational hypertension, preeclampsia and/or mild chronic hypertension.
Non HT SGA= all women in the remainder of the cohort who did not have Hypertensive-SGA pregnancies.
doi:10.1371/journal.pone.0070917.t005
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3000 g and 3499 g was a significant predictor. The AUC for the
clinical variables identified at 1561 weeks’ for prediction of
Hypertensive-SGA was 0.76. Addition of mean uterine artery
Doppler resistance indices resulted in an improvement of the
model (AUC=0.82). There was no change in the AUC in the
validation cohort (0.76 for clinical alone and 0.82 for clinical plus
ultrasound) (Figure 2C).
The test characteristics for prediction of All-SGA, Normoten-
sive-SGA and Hypertensive-SGA at 5%, 10% and 25% false
positive rates in the validation dataset are shown in table 6.
Discussion
In the large international prospective SCOPE study we have
identified a number of factors present in the first half of pregnancy
which are associated with later development of SGA. The models
detailed above may be considered as the first step towards the
development of a personalised algorithm for prediction of SGA in
healthy nulliparous women to which biomarkers will be added as
the next step. Although All-SGA was undertaken initially, the
rationale for considering the prediction of Normotensive and
Hypertensive-SGA separately include the largely different pheno-
types and the more severe perinatal outcomes in Hypertensive-
SGA. Metabolic syndrome features such as obesity, higher blood
pressure and family history of metabolic disease are predominant
in the Hypertensive-SGA model whereas in Normotensive-SGA
factors such as smoking and vigorous exercise are incorporated.
Predictors for All-SGA reflect a combination of the Normoten-
sive and Hypertensive-SGA sub-groups. The area under the ROC
curve for prediction of All-SGA infants in the validation database
using clinical risk factors recorded at the 1561 weeks’ gestation
was 0.63 which increased to 0.69 with addition of fetal growth and
mean uterine artery Doppler parameters from the 2061 weeks’
anatomy scan. At a false positive rate of 10% and 25%, 26% and
52% of All-SGA pregnancies respectively were identified in the
validation database. This is comparable to detection rates reported
in routine clinical practice and with the use of customised
antenatal growth charts respectively [7]. We defined SGA as
birthweight less than the tenth customised centile, which is better
associated with pathological fetal growth than SGA defined as
birthweight less than the tenth population centile [3,18,19].
However a proportion of these small babies will inevitably still be
constitutionally small and healthy.
Not surprisingly the predictors for All-SGA we identified in this
study are very similar to the risk factors that we reported after the
first 3500 women had been recruited to the SCOPE study [9].
Lower maternal birthweight and cigarette smoking are well
described risk factors for SGA infants [9]. As has previously been
reported women who undertook daily vigorous exercise had a
greater than three-fold increase in risk of SGA [9], perhaps
mediated by reduced uterine blood flow [9,20]. Interestingly
women who undertook moderate exercise (defined as recreational
walking $four times weekly) had a 27% reduction in risk. This
latter novel finding with regard to protection from SGA, supports
the American College of Obstetrics and Gynaecology Guidelines
recommendation that low to moderate intensity exercise should be
encouraged in pregnancy [21]. The biological mechanism is
unclear but may be related to improved cardiovascular function
and insulin sensitivity in pregnant women who exercise [22,23].
We also re-confirmed that Rhesus negative maternal blood group
is a non-modifiable protective factor associated with an approx-
imate 40% reduction in risk of SGA. The gene encoding the
Rhesus factor lies within a group of genes on chromosome 1 which
are associated with transportation mechanisms into cells for several
molecules including zinc, glucose and ammonia [24] which may
explain the protective effect on fetal growth found in this and our
previous study [9]. Additionally we found that increasing maternal
random glucose at 1561 weeks’ was protective for SGA which is
consistent with findings from the HAPO study which demonstrat-
ed a continuous relationship between increasing maternal glucose
and birthweight [25].
Consistent with data from our previous publication [8] the large
majority of SGA infants in this study (73.8%) were born to
mothers who remained normotensive in pregnancy and hence
there is substantial overlap between All-SGA and Normotensive-
SGA predictors and similar performance of the two models with
area under the ROC curve for prediction of Normotensive-SGA
infants in the validation database using clinical risk factors of 0.62
Table 6. Prediction of All-SGA, Normotensive-SGA and Hypertensive-SGA based on clinical risk factors at 1561 weeks’ combined
with ultrasound factors at 2061 weeks’ gestation in a nulliparous cohort using cut-offs at 5%, 10%, and 25% false positive rates.
No (%) with abnormal test result Sensitivity Specificity PPV NPV
Positive Likelihood
ratio
Negative Likelihood
ratio
All-SGA Validation cohort
114 (6.2%) 15 (11 to 20) 95 (94 to 96) 27 (20 to 36) 90 (89 to 91) 3.0 (2.0 to 4.4) 0.90 (0.84 to 0.94)
218 (11.8%) 26 (21 to 32) 90 (89 to 91) 24 (19 to 30) 91 (90 to 91) 2.6 (1.9 to 3.4) 0.83 (0.76 to 0.89)
517 (27.9%) 52 (45 to 58) 75 (74 to 76) 21 (18 to 23) 93 (92 to 94) 2.1 (1.7 to 2.4) 0.65 (0.56 to 0.74)
Normotensive-SGA Validation
cohort
109 (5.9%) 16 (10 to 23) 95 (94 to 96) 21 (14 to 30) 93 (92 to 94) 3.1 (2.0 to 4.8) 0.89 (0.83 to 0.95)
217 (11.7%) 31 (23 to 39) 90 (88 to 91) 21 (16 to 27) 94 (92 to 95) 3.1 (2.3 to 4.1) 0.77 (0.69 to 0.86)
505 (27.3%) 53 (45 to 61) 75 (73 to 77) 15 (12 to 19) 95 (94 to 96) 2.1 1.8 to 2.5) 0.63 (0.53 to 0.74)
Hypertensive SGA Validation
cohort
111 (6.0%) 34 (22 to 47) 95 (94 to 96) 18 (12 to 27) 98 (97 to 98) 6.7 (4.4 to 10.0) 0.70 (0.58 to 0.84)
206 (11.1%) 44 (31 to 58) 90 (88 to 91) 13 (9 to 18) 98 (97 to 99) 4.4 (3.2 to 6.0) 0.62 (0.50 to 0.78)
492 (26.6%) 71 (58 to 82) 75 (73 to 77) 9 (6 to 11) 99 (98 to 99) 2.8 (2.4 to 3.4) 0.38 (0.26 to 0.57)
doi:10.1371/journal.pone.0070917.t006
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increasing to 0.69 with addition of ultrasound parameters from the
2061 weeks’ anatomy scan. At a false positive rate of 10% and
25%, 31% and 53% of Normotensive-SGA pregnancies respec-
tively were identified in the validation database. As for All-SGA
prediction models, these rates are comparable to detection rates in
current clinical practice [7].
The performance of our model for Normotensive-SGA is
comparable to a previous report for prediction of SGA pregnan-
cies in mothers without preeclampsia which combined uterine
artery Doppler, blood pressure and biomarkers at 11–13 weeks’
gestation and identified 50% of later SGA pregnancies [26]. We
have recently reported an AUC of 0.9 for prediction of SGA at 15
weeks’in a matched case (n = 40) control (n = 40) sub-group of
SCOPE participants without preeclampsia (and therefore pre-
dominantly Normotensive-SGA) using a combination of 19
metabolites including sphingolipids, phospholipids, carnitines,
and fatty acids [27]. We are therefore optimistic that improved
prediction of Normotensive-SGA will be achievable in the next
phase of SCOPE research program, in which we plan to combine
clinical risk factors with measurement in all participants of
multiple placental, endothelial and cardiovascular biomarkers,
representing different potential pathways in the pathogenesis of
SGA [28]. In line with this approach, a recent systematic review of
biomarkers for predicting fetal growth restriction has demonstrat-
ed poor predictive ability of single biomarkers and also recom-
mended combinations of clinical factors with biophysical param-
eters and multiple biomarkers in future studies [29].
With the exception of dietary factors, the predictors for
Normotensive-SGA we identified in this study are very similar to
the risk factors that we reported after the first 3500 women had
been recruited to the SCOPE study [9]. SCOPE participants in
the training and validation data-sets in this study were stratified by
the geographical areas of Australasia and Europe whereas in the
earlier study the large majority of participants were from
Auckland, New Zealand (58%) and Adelaide, Australia (32%).
The balanced geographic distribution in the current study may
explain why the previously identified risk factors of pre-pregnancy
fruit and vegetable intake, which were very low in the Adelaide
participants, were no longer associated with Normotensive-SGA in
this study [30]. Currently attending University was associated with
All-SGA and Normotensive-SGA.We are unable to explain this
relationship which we believe is unlikely to be causal and more
likely to be related to residual confounding. It is unlikely to be a
surrogate for higher socioeconomic status which should reduce the
risk of SGA [28].
Prediction of Hypertensive-SGA infants by our algorithm using
clinical characteristics, achieved an AUC of 0.76 which was
increased to 0.82 by the addition of ultrasound variables from the
20 week scan in the validation model. At a false positive rate of
10% and 25%, 44% and 71% of Hypertensive-SGA pregnancies
were identified in the validation database. A detection rate of 71%
using this model is considerably better than routine practice [10]
and is two and a half times greater than the 28% detection rate of
hypertensive SGA in the current study. This is an important sub-
group of SGA pregnancies to predict antenatally given the
increased rates of preterm delivery and more severe fetal growth
restriction we have demonstrated, both of which are associated
with increased rates of long term adverse neurological outcomes
[31].
Other factors, including smoking [32,33], alcohol intake [34],
maternal birthweight [35], increasing body mass index [33],
increasing blood pressure [36] and increasing uterine artery
Doppler indices [37] previously identified as being associated with
SGA were also included in our model of Hypertensive-SGA.
Furthermore, the variables included in our Hypertensive-SGA
prediction model are very similar to those which we recently
reported as predictors of preeclampsia [10]. This is interesting as
less than half of Hypertensive-SGA pregnancies in our cohort had
preeclampsia (42%) and the majority group had gestational
hypertension (57%) with only 1% with chronic hypertension.
This finding suggests that predictors for gestational hypertension
associated with SGA pregnancies and preeclampsia may be very
similar [38].
Several previous studies which have aimed to predict late
pregnancy complications such as preeclampsia and SGA have
used heterogeneous populations of mixed parity which included
women with well-established risk factors [26,36] limiting general-
izability of findings. In the SCOPE study our goal is to predict late
pregnancy complications in healthy nulliparous women. The
reasons for this are several-fold: nulliparous women comprise
.40% of births: in the United Kingdom [39], Ireland [40],
Australia [41] and New Zealand [42], they have significantly
higher rates of preeclampsia, SGA and spontaneous preterm birth
than multiparous women, they do not have a past obstetric history
to guide risk selection, and screening results are more likely to be
generalizable to other groups of healthy nulliparous women. We
also elected to develop the SCOPE screening tests based primarily
on data collected at 1561 weeks’ of gestation rather than in the
first trimester. The reasons for this approach are that preventative
therapy with low dose aspirin is effective for reduction of
preeclampsia and SGA when initiated at 16 and up to 20 weeks’
gestation [43,44], more women have booked for antenatal care
and biomarker discrimination in particular with PlGF has been
shown to improve between samples obtained in the first trimester
and 15–16 weeks’ [45].
For each SGA predictive model there was a 5–6% increase in
performance with addition of fetal size and/or Doppler indices
from the 2061 weeks’ anatomy scan. We are not advocating
incorporating uterine artery Doppler as a routine component of
the 20 week anatomy scan as the performance of our algorithms is
currently not good enough for application in clinical practice. We
will be able to comment further on the utility of 20 week Doppler
studies after biomarkers are added to the clinical algorithms in the
next phase of our SCOPE research.
The urgent need for improved prediction of SGA pregnancies is
highlighted by the fact that only one quarter (24.5%) of all SGA
infants were identified before birth in our cohort. Improved
detection accompanied by good management has been associated
with reduced mortality and severe morbidity in SGA infants [6]
and is a high priority in antenatal care. It was disappointing that
antenatal identification was not significantly improved in Hyper-
tensive-SGA pregnancies (27.9% in Hypertensive-SGA vs 23.4%
in Normotensive-SGA p=0.35). It is well described that
preeclampsia is associated with a two to three fold increase in
risk whereas gestational hypertension is associated with an
approximately 50% increase in risk of SGA [8,46]. Women with
hypertensive complications in late pregnancy should therefore
have a growth scan unless delivery is to be undertaken forthwith,
in which case the fetus should be monitored carefully during the
delivery process.
The strengths of our study included its prospective design,
excellent follow up of a large cohort (98.7%), and real-time data
monitoring procedures that helped ensure the quality of the data.
The comparison group for our predictive models was all other
women. For example for Normotensive-SGA the comparison
group was all women without Normotensive-SGA (which included
Hypertensive-SGA and other pregnancy complications) and for
Hypertensive-SGA it was women without Hypertensive-SGA,
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which included those with Normotensive-SGA. Some previous
studies aiming to predict preeclampsia or SGA have used women
with uncomplicated pregnancies as the referent group [47,48].
This artificially enhances test performance and also does not
reflect the real clinical situation where at the beginning of
pregnancy late pregnancy outcome is unknown.
Our rich database contains variables covering all known and
hypothesised risk factors based on biological plausibility for SGA
infants. A limitation imposed by this study design and our wealth
of data is that we could not pre-select a limited number of
variables based on prior knowledge and biological plausibility for
our logistic regression models.
Conclusions
In a large cohort of healthy nulliparous women we report
combinations of clinical and ultrasound variables obtained in the
first half of pregnancy associated with later development of SGA.
Future addition of multiple biomarkers to our clinical and
ultrasound algorithms may enable reliable risk prediction,
especially of Hypertensive-SGA pregnancies. If successful this will
enable monitoring and timely delivery of these SGA infants with
the potential to reduce both morbidity and mortality.
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